These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 23831405)
1. [Observational studies: the hazard and other gods]. Arenas-Fernández J; Fernández-Martín JL; Cannata-Andía JB; Martínez-Camblor P Med Clin (Barc); 2014 Jan; 142(2):80-4. PubMed ID: 23831405 [No Abstract] [Full Text] [Related]
2. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate]. Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857 [TBL] [Abstract][Full Text] [Related]
3. RenaGel efficacy in severe secondary hyperparathyroidism. Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746 [TBL] [Abstract][Full Text] [Related]
4. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. Iseki K Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161 [TBL] [Abstract][Full Text] [Related]
7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700 [TBL] [Abstract][Full Text] [Related]
8. [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis]. Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H Clin Calcium; 2005 Sep; 15 Suppl 1():192-9. PubMed ID: 16279024 [No Abstract] [Full Text] [Related]
9. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism. Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764 [TBL] [Abstract][Full Text] [Related]
10. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology]. Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P; G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960 [TBL] [Abstract][Full Text] [Related]
11. Propensity score matching for estimating a marginal hazard ratio. Wang T; Zhao H; Yang S; Tang S; Cui Z; Li L; Faries DE Stat Med; 2024 Jun; 43(14):2783-2810. PubMed ID: 38705726 [TBL] [Abstract][Full Text] [Related]
12. Reporting of Limitations of Observational Research. Wang MT; Bolland MJ; Grey A JAMA Intern Med; 2015 Sep; 175(9):1571-2. PubMed ID: 26053740 [No Abstract] [Full Text] [Related]
13. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407 [TBL] [Abstract][Full Text] [Related]
14. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Jean G; Chazot C; Charra B Nephrol Dial Transplant; 2007 Jul; 22(7):2102-3. PubMed ID: 17395648 [No Abstract] [Full Text] [Related]
15. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina. Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157 [TBL] [Abstract][Full Text] [Related]
16. Treatment of hyperparathyroidism--why is it crucial to control serum phosphate? Brancaccio D; Gallieni M; Cozzolino M Nephrol Dial Transplant; 1996 Mar; 11(3):420-3. PubMed ID: 8671808 [No Abstract] [Full Text] [Related]
17. Testing causal effects in observational survival data using propensity score matching design. Lu B; Cai D; Tong X Stat Med; 2018 May; 37(11):1846-1858. PubMed ID: 29399833 [TBL] [Abstract][Full Text] [Related]
18. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy]. Zucchi C Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697 [No Abstract] [Full Text] [Related]
19. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Kazama JJ; Gejyo F; Shigematsu T; Fukagawa M Ther Apher Dial; 2005 Aug; 9(4):328-30. PubMed ID: 16076376 [TBL] [Abstract][Full Text] [Related]